Cargando…
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models
Prolonged activation of vascular endothelial growth factor receptor-2 (VEGFR-2) due to mis-regulation of the VEGF pathway induces aberrant blood vessel expansion, which supports growth and survival of solid tumors. Therapeutic interventions that inhibit the VEGFR-2 pathway have therefore become a ma...
Autores principales: | Li, Yanxia, Amaladas, Nelusha, O’Mahony, Marguerita, Manro, Jason R., Inigo, Ivan, Li, Qi, Rasmussen, Erik R., Brahmachary, Manisha, Doman, Thompson N., Hall, Gerald, Kalos, Michael, Novosiadly, Ruslan, Puig, Oscar, Pytowski, Bronislaw, Schaer, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292077/ https://www.ncbi.nlm.nih.gov/pubmed/35849586 http://dx.doi.org/10.1371/journal.pone.0268244 |
Ejemplares similares
-
Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy
por: Lowery, Caitlin D., et al.
Publicado: (2019) -
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
por: Holmgaard, Rikke B., et al.
Publicado: (2018) -
High-content molecular profiling of T-cell therapy in oncology
por: Novosiadly, Ruslan, et al.
Publicado: (2016) -
Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation
por: Huggenberger, Reto, et al.
Publicado: (2010) -
Ly phenotype of cytotoxic T cells for syngeneic tumor
Publicado: (1976)